DiaMedica Reports Increased Q1 Loss, Clinical Trial Delays for Key Programs, and Higher Cash Burn

summarizeSummary

DiaMedica Therapeutics reported a wider Q1 net loss and increased cash burn, coupled with significant delays and challenges in its pivotal ReMEDy2 stroke trial and its U.S. preeclampsia program.

check_boxKey Events

• Increased Net Loss and Cash Burn

  The company reported a Q1 2026 net loss of $10.04 million, an increase from $7.71 million in Q1 2025, with net cash used in operating activities rising to $9.1 million from $7.1 million in the prior year period.

• Clinical Trial Delays for ReMEDy2 (AIS)

  DiaMedica continues to experience slower than expected site activations and enrollment in its Phase 2/3 ReMEDy2 trial for acute ischemic stroke, leading to an estimated interim analysis completion in Q4 2026.

• US Preeclampsia Program Faces Delay

  The U.S. Phase 2 study for preeclampsia is delayed as the FDA requested an additional non-clinical study, and preliminary results from the rabbit model indicate an antibody response, preventing its completion as planned.

• Adequate Near-Term Liquidity

  As of March 31, 2026, the company had $51.3 million in combined cash, cash equivalents, and marketable securities, which is expected to fund planned operations for at least the next 12 months.

auto_awesomeAnalysis

DiaMedica Therapeutics Inc. reported a significant increase in its net loss and cash burn for Q1 2026, alongside critical updates regarding its clinical development programs. The net loss widened to $10.04 million, exceeding analyst estimates, driven by higher research and development expenses. More importantly, the company disclosed ongoing challenges with its Phase 2/3 ReMEDy2 trial for acute ischemic stroke, including slower site activations and enrollment, which has pushed the interim analysis to Q4 2026. Additionally, the U.S. preeclampsia program faces delays due to an FDA request for an additional non-clinical study and issues with the chosen animal model. While the company maintains sufficient liquidity for the next 12 months, these operational and clinical setbacks are material for a clinical-stage biotech and could impact future financing efforts and timelines for product development.